Given the surge in GLP-1 agonist use in treatment of diabetes and obesity, further prospective studies are needed to investigate the impact of GLP-1 agonists on RGC rates based on therapeutic indication, which can ultimately help guide endoscopy-related and peri-procedure recommendations. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.